A clinical, evidence-graded monograph for every peptide.
The Peptide Encyclopedia is our A-Z reference of individual peptide monographs. Each entry covers what a peptide is, how it works, the strength of the human and preclinical evidence behind it (graded A-D), the doses and routes reported in the literature, its documented risks, and its current FDA and anti-doping status — every claim tied to a real, verifiable source. It is the reference spine of the site, written for readers who want the clinical record rather than the hype.
A clinical monograph on Pentapeptide-18 (Leuphasyl) — the enkephalin-derived, presynaptic cosmetic peptide marketed alongside the SNAP-25-mimetic Argireline. One small human study, manufacturer synergy data, and a poor-delivery caveat.
A clinical monograph on SLU-PP-332 — the synthetic pan-ERR agonist sold as an 'exercise mimetic.' It is not a peptide, has zero human trials, and is functionally banned in sport.
Peptide EncyclopediaA clinical monograph on sermorelin — the GHRH(1-29) growth-hormone secretagogue once FDA-approved for diagnosis and pediatric GH deficiency. Real but modest, mostly pre-2000 human trials; the anti-aging marketing outruns the data.
Peptide EncyclopediaA clinical monograph on examorelin — the International Nonproprietary Name for hexarelin, a synthetic hexapeptide growth-hormone secretagogue. Small human pharmacodynamic trials (Grade B), never approved, and WADA-prohibited at all times.
Peptide EncyclopediaA clinical monograph on orforglipron — the first oral, non-peptide small-molecule GLP-1 receptor agonist, FDA-approved as Foundayo in 2026 for chronic weight management, with Grade A Phase 3 RCT evidence.
Peptide EncyclopediaA clinical monograph on Semax — the Russian-developed ACTH(4-10) heptapeptide used intranasally for stroke recovery and cognition. Real but single-country human data, graded B, with an unsettled 2026 FDA status.
Peptide EncyclopediaA clinical monograph on Noopept (omberacetam) — the proline-glycine dipeptide nootropic and cycloprolylglycine prodrug. Small Russian human trials in cognitive impairment, a deep preclinical mechanism, and an unsettled 2026 legal status.
Peptide EncyclopediaA clinical monograph on semaglutide — the long-acting GLP-1 receptor agonist behind Ozempic, Wegovy and Rybelsus. Grade-A human RCT evidence across diabetes, obesity, cardiovascular, kidney and liver disease.
Peptide EncyclopediaA clinical monograph on Selank (TP-7) — the Russian tuftsin-analog anxiolytic peptide. Small human anxiety trials, a mostly preclinical mechanism, and an unsettled 2026 US legal status.
Peptide EncyclopediaA clinical monograph on retatrutide (LY3437943) — Eli Lilly's investigational triple GIP/GLP-1/glucagon agonist with the largest pharmacologic weight loss reported to date, graded A on human Phase 3 RCTs, but FDA-unapproved and WADA-prohibited as of mid-2026.
Peptide EncyclopediaA clinical monograph on PTD-DBM — the CXXC5-Dishevelled disrupting peptide engineered to reactivate Wnt/β-catenin signaling for hair regrowth. Strong target biology, mouse-only efficacy, and no human trials.
Peptide EncyclopediaA clinical monograph on PT-141 (bremelanotide) — the centrally acting melanocortin agonist FDA-approved as Vyleesi for premenopausal HSDD. Grade-A human RCT data, a narrow label, and a real pressor and pigmentation safety profile.
Peptide EncyclopediaA clinical monograph on Prostamax — the synthetic prostate-tropic tetrapeptide Lys-Glu-Asp-Pro (KEDP) from the Khavinson school. The human prostate evidence belongs to the parent bovine-prostate extract, not the synthetic peptide.
Peptide EncyclopediaA clinical monograph on pramlintide — the synthetic amylin analog and only non-insulin mealtime adjunct FDA-approved for type 1 and type 2 diabetes, with Grade-A human RCT evidence and a boxed warning for severe hypoglycemia.
Peptide EncyclopediaA clinical monograph on pentosan polysulfate (Elmiron) — the FDA-approved interstitial-cystitis drug that is not a peptide, its off-label knee-osteoarthritis use, and its serious cumulative-dose eye risk.
Peptide EncyclopediaA clinical monograph on Pentadeca Arginate (PDA) — the L-arginine salt of BPC-157 marketed for tendon, gut and wound healing. Zero PDA-specific studies, borrowed preclinical data, and an unsettled 2026 legal status.
Peptide EncyclopediaA clinical monograph on Pentadeca Arginate — the L-arginine salt of BPC-157. No studies exist under the 'PDA' name; the borrowed parent evidence is 35:1 preclinical, with zero human RCTs and an unsettled 2026 legal status.
Peptide EncyclopediaA clinical monograph on PEG-MGF — the pegylated Mechano Growth Factor E-peptide marketed for muscle repair and recovery. Preclinical-only evidence, no human trials, and a restricted 2026 legal status.
Peptide EncyclopediaA clinical monograph on Palmitoyl Tripeptide-1 (pal-GHK) — the lipid-anchored GHK matrikine and half of Matrixyl 3000. Small vehicle-controlled topical trials, strong in-vitro mechanism, and a settled cosmetic legal status.
Peptide EncyclopediaA clinical monograph on P21 (P021, Ac-DGGLAG-NH2) — a small-molecule CNTF mimetic marketed as a nootropic peptide. Reproducible rodent neurogenesis and anti-tau data, but zero human trials and an unapproved-research-chemical status.
A peptide monograph is a single, structured reference page for one peptide. On PeptideVox each monograph covers identity and chemistry, mechanism of action, the indication-by-indication evidence (each graded A-D), reported dosing and routes from the literature, safety and contraindications, and current legal and anti-doping status. Every efficacy claim carries an evidence grade and an inline citation to a real study, regulatory document, or trial registry so you can check the source yourself. The format is informational and editorial — it is not medical advice.
PeptideVox grades every efficacy claim on an A-D scale. Grade A means human randomized controlled trials or meta-analyses support the claim; grade B means lower-tier human evidence such as cohort or open-label studies; grade C means preclinical only (animal or in-vitro) with no qualifying human efficacy data; and grade D means anecdotal, mechanistic-only or marketing claims with no controlled evidence. Grading is deliberately conservative — preclinical promise never earns an A or B, and the grade always reflects the human-evidence level when human and animal data conflict.
No. The encyclopedia is strictly informational and editorial. It does not recommend vendors, link to sellers of unapproved peptides, or tell you how to source or self-administer anything. Dosing figures are reported only as they appear in the published literature and clinical or anecdotal use, for completeness — never as a protocol to follow. Many peptides covered here are not FDA-approved, are sold as "research chemicals not for human use," and may be prohibited in sport. Always consult a licensed clinician before any health decision.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.
